RecruitingPhase 2

Clinical Efficacy and Mechanism Exploration of MR-61 in Delaying the Progression of Myopia

China164 participantsStarted 2025-10-01

Plain-language summary

To investigate whether probiotic MR-61 can assist in slowing down the progression rate of myopia (a prospective randomized controlled study).

Age range3 Years – 18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Myopia is defined as spherical equivalent (SE) ≤ -0.5D.
✓. Aged between 3 and 18 years, with no restriction on gender.
✓. Cylinder power ≤ 1.50D; anisometropia of SE between both eyes ≤ 1.50D.
✓. The subject has sufficient compliance with the study follow-up; the subject or their guardian has the intention to receive treatment and has signed the informed consent form.

✕. Presence of other concomitant ocular diseases;
✕. Abnormal findings on clinical slit-lamp examination;
✕. Existence of amblyopia, manifest strabismus, esotropia, or other congenital ocular diseases;
✕. Individuals with abnormal intraocular pressure or abnormal axial length of the eye;
✕. Either or both parents having a spherical equivalent (SE) ≤ -6.00D;
✕. Other conditions inconsistent with this study.

Change in Spherical Equivalent Refraction

Timeframe: Measured at baseline, 1, 3, 6, 9, 12, 13, 14, 19, and 25 months post-intervention.

NCT IDNCT07298824

SponsorSecond Affiliated Hospital of Nanchang University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-07-01

Yifeng Yu, Ph.D